For informational and research purposes only. Not medical advice. Content is aggregated from public sources. Always consult a qualified healthcare provider.
Healing & Recovery · Comparison

BPC-157 vs BPC-157 + TB-500 Stack

A neutral, side-by-side comparison of two healing & recovery peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.

BPC-157BPC-157 + TB-500 Stack
CategoryHealing & RecoveryHealing & Recovery
Also known asBody Protection Compound 157, PL 14736, Pentadecapeptide BPC 157Wolverine Stack, BPC TB500 combination, healing stack, BPC-157 TB-500
EvidencePreclinical onlyResearch-stage
Dosing range200mcg–1000mcg mcg, once or twice dailyBPC-157 250mcg + TB-500 2.5mg–BPC-157 750mcg + TB-500 7.5mg varies by component, 2–3x per week
AdministrationSubcutaneous injection (most common), Intramuscular injection, Oral (reduced bioavailability — used for gut-specific protocols)Subcutaneous injection, Intramuscular injection
Key side effectsNausea (rare, typically at higher doses), Dizziness / lightheadedness shortly after injection (uncommon, anecdotal), Injection site redness or irritation, Human safety profile is not established — no controlled human trialsBPC-157: nausea (rare), dizziness, lightheadedness, TB-500: fatigue, headache, injection site reactions, No documented combination-specific adverse effects, Theoretical oncological considerations (angiogenesis stimulation) — relevant in cancer history
Cited sources6 references2 references

Key differences

  • Evidence level differs: BPC-157 is preclinical only, while BPC-157 + TB-500 Stack is research-stage.
  • Administration: BPC-157 — Subcutaneous injection (most common), Intramuscular injection, Oral (reduced bioavailability — used for gut-specific protocols); BPC-157 + TB-500 Stack — Subcutaneous injection, Intramuscular injection.
  • Dosing units differ: BPC-157 is dosed in mcg, BPC-157 + TB-500 Stack in varies by component — they operate at different scales.
  • Frequency: BPC-157 is typically once or twice daily; BPC-157 + TB-500 Stack is 2–3x per week.
  • Research depth: this profile cites 6 sources for BPC-157 vs 2 for BPC-157 + TB-500 Stack.

How each works

BPC-157

Preclinical rodent and in-vitro studies — predominantly from the Sikiric group in Zagreb, with mechanistic angiogenesis work from Pang's group in Taiwan — report accelerated healing of tendon, ligament, muscle, and gut tissue. Proposed mechanisms include modulation of the nitric oxide (NO) system, promotion of angiogenesis via the VEGFR2–Akt–eNOS pathway, upregulation of growth factor signaling, and effects along the gut–brain axis. Despite a large and internally consistent animal literature, BPC-157 has no completed human clinical efficacy trials and is an unapproved drug.

BPC-157 + TB-500 Stack

BPC-157 and TB-500 work through entirely non-overlapping mechanisms and have been combined in numerous community protocols for injury recovery. BPC-157 drives angiogenesis and growth factor receptor expression; TB-500 regulates actin polymerization and cell migration into the injury site. No documented negative interactions exist — the combination is considered synergistic in the healing research community based on the complementary biology of each compound.

Read the full BPC-157 profileRead the full BPC-157 + TB-500 Stack profile

This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.